Inoviem Scientific, a Strasbourg, France-based Contract Research Biotech (CRB) company, received €545k (approx. $611k) in funding.
French public investment bank bpifrance provided the financial resources.
There are two elements to the funding:
– A zero-interest innovation loan of €295k ($331k) for development and automation of its existing innovative technology and the development of further ‘label-free’ technologies under physiological conditions; and
– A France Europe Innovation (FEI) loan of €250k ($280k) to automate its NPOT (Nematic Protein Organization Technique) technology to increase sample throughput and revenue potential.
Founded in 2011 by Dr. Pierre Eftekhari, chairman, Inoviem Scientific is an innovation and technological driven Contract Research Biotech (CRB) that aims to support pharmaceutical and biotechnology industry clients in developing safer pharmacological agents.
It leverages two proprietary technologies to offer pharmaceutical players increased speed and enhanced safety at all stages of drug development from drug discovery (the identification of secondary targets and detection of potential adverse effects, etc.) through to clinical trials (with patient stratification and identification of biomarkers, etc.).